Biogen (NASDAQ:BIIB), one of the best performing big biotechs of 2013, reported solid third-quarter results today and hovered around an all-time high, but shares were up less than 1% when the market closed. In the following video, from The Motley Fool's health-care show Market Checkup, analysts Max Macaluso and David Williamson discuss the updated results from the launch of Biogen's newest multiple sclerosis drug, Tecfidera, and reasons why the company's hemophilia A drug Eloctate put a damper on today's results.
Alison Southwick owns shares of Apple. David Williamson owns shares of Facebook. Max Macaluso, Ph.D., owns shares of Apple and Facebook. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.